Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification.
Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification.
复制标题
通过聚合酶链式反应扩增检测到美国献血者体内存在乙型肝炎和丙型肝炎病毒基因组。
DOI：
10.1002/jmv.1890420210
复制
发表时间：
1994
影响因子：
12.7
通讯作者：
Wands,JR
中科院分区：
文献类型：
--
作者：
Liang,TJ;BodenheimerJr,HC;Yankee,R;Brown,NV;Chang,K;Huang,J;Wands,JR
丙型肝炎病毒（HCV）是全球输血后肝炎的主要原因。与B型肝炎病毒（HBV）相关的输血后肝炎继续发生。1987年至1988年期间，使用更敏感的技术对来自罗得岛血液中心的HBsAg阴性供体血清进行筛查，以评估低水平HBV感染的患病率。第一组由866名无HBV血清学标志物的健康献血者组成，第二组由377名ALT升高（> 45 IU/L）的献血者组成，第二组由148名抗HBc阳性的献血者组成，第四组由8名两种替代标志物阳性的献血者组成。采用灵敏的单克隆免疫放射测定法（M-IRMA）检测血清中的HBsAg相关表位（检测限为20 pg/ml）。使用抗-HBs捕获血清中HBV相关病毒粒子，然后进行聚合酶链反应（PCR）扩增的方法，分析血清子集中HBV DNA的存在。Ⅰ组HBsAg和HBV DNA阳性率分别为0.8%和1.7%。与此相反，在组II和组III分别为0.9%和9.5%和0.7%和18.1%的阳性。有8名献血者ALT升高和抗HBc;其中4名（50%）HBV DNA阳性。在抗-HBc组中，大多数（80%）HBV DNA供体无或低（信噪比<10）抗-HBs滴度。使用抗HCV检测和逆转录PCR检测HCV基因组，我们在49名低水平HBV DNA的供体中检测到9名HCV感染的证据。
Hepatitis C virus (HCV) represents a major cause of posttransfusion hepatitis worldwide. Post‐transfusion hepatitis associated with hepatitis B virus (HBV) continues to occur. HBsAg‐negative donor sera from the Rhode Island Blood Center between 1987 and 1988 were screened using more sensitive techniques to assess the prevalence of low level HBV infection. Group I consists of 866 healthy blood donors without HBV sero‐logic markers, group II consists of 377 donors with ALT elevations (>45 IU/L), group II consists of 148 donors positive for anti‐HBc, and group IV consists of eight donors positive for both surrogate markers. A sensitive monoclonal immuno‐radiometric assay (M‐IRMA) was employed for detection of HBsAg‐associated epitopes (detection limit of 20 pg/ml) in serum. A subset of sera were analyzed for the presence of HBV DNA using the method of anti‐HBs capture of HBV related virions in serum followed by polymerase chain reaction (PCR) amplification. Using these techniques, 0.8% and 1.7% of donors were positive for HBsAg and HBV DNA respectively in group I. In contrast, 0.9% and 9.5% in group II and 0.7% and 18.1% in group III were positive, respectively. There were eight donors with both ALT elevation and anti‐HBc; and four (50%) of these were positive for HBV DNA. In the group with anti‐HBc, the majority (80%) of donors with HBV DNA had either no or low (signal to noise ratio < 10) anti‐HBs titer. Using anti‐HCV testing and reverse transcription‐PCR for detection of HCV genomes, we detected evidence of HCV infection in nine of the 49 donors with low level HBV DNA.